The pathophysiology of how hyperkalemia develops is typically ... In a recent comparison of the ACE inhibitor lisinopril with the ARB valsartan in patients with renal insufficiency or diabetes ...

but not for ACE inhibitor dosage. Ten percent of the study patients developed severe hyperkalemia (≥6.0 meq/mL). The OR for the development of severe hyperkalemia was 3.36 for each progressive ...

The drug can sometimes cause life-threatening hyperkalemia, however, when used in combination with angiotensin-converting enzyme (ACE) inhibitors (which are also indicated for heart failure).

Angiotensin converting enzyme inhibitors are a class of oral medications that act primarily through blockade of the angiotensin converting enzyme. This enzyme converts angiotensin I to angiotensin II.

Five patients taking spironolactone and one patient on placebo developed hyperkalemia within ... adding spironolactone to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor ...

Monitor for hyperkalemia with drugs that inhibit the renin-angiotensin-aldosterone sytem (eg, ACE inhibitors, ARBs, spironolactone, eplerenone, aliskiren), or NSAIDs. Anticholinergics, other ...